Alyx B. Porter, M.D.

  1. Neurologist

出版物

  1. Ramos-Fresnedo A, Domingo RA, Perez-Vega C, Pullen MW, Akinduro OO, Almeida JP, Jentoft ME, Bendok BR, Chaichana KL, Trifiletti DM, Burns TC, Porter AB, Kizilbash SH, Middlebrooks EH, Quinones-Hinojosa A, Sherman WJ. The early infiltrative phase of GBM hypothesis: are molecular glioblastomas histological glioblastomas in the making? A preliminary multicenter study. J Neurooncol. 2022 Jul; 158 (3):497-506 Epub 2022 June 14
    View PubMed
  2. Rivera Perla KM, Tang OY, Durfey SNM, Vivas-Buitrago T, Sherman WJ, Parney I, Uhm JH, Porter AB, Elinzano H, Toms SA, Quinones-Hinojosa A. Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI). J Neurooncol. 2022 Jul; 158 (3):349-357 Epub 2022 May 03
    View PubMed
  3. Ramos-Fresnedo A, Pullen MW, Perez-Vega C, Domingo RA, Akinduro OO, Almeida JP, Suarez-Meade P, Marenco-Hillembrand L, Jentoft ME, Bendok BR, Trifiletti DM, Chaichana KL, Porter AB, Quinones-Hinojosa A, Burns TC, Kizilbash SH, Middlebrooks EH, Sherman WJ. The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study. J Neurooncol. 2022 Mar; 157 (1):177-185 Epub 2022 Feb 17
    View PubMed
  4. Porter AB, Liu H, Kohli S, Cerhan JL, Sloan J, McMurray RP, Le-Rademacher J, Loprinzi CL, Villano JL, Kizilbash SH, Mehta MP, Jaeckle KA, Brown PD. Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Feb 1; 8 (2):259-267
    View PubMed
  5. Chukwueke UN, Hervey-Jumper S, Porter A. Disparities and Inequities Among Patients with Central Nervous System Tumor. Hematol Oncol Clin North Am. 2022 Feb; 36 (1):e1-e8
    View PubMed
  6. Reihl SJ, Patil N, Morshed RA, Mehari M, Aabedi A, Chukwueke UN, Porter AB, Fontil V, Cioffi G, Waite K, Kruchko C, Ostrom Q, Barnholtz-Sloan J, Hervey-Jumper SL. A Population Study of Clinical Trial Accrual for Women and Minorities in Neuro-Oncology Following the NIH Revitalization Act. Neuro Oncol. 2022 Jan 6 Epub 2022 Jan 06
    View PubMed
  7. Rosenow CS, Dawit S, Farrugia LP, Henry Ma KA, Sharma A, McKeon A, Porter AB, Grill MF. Case Report: Opsoclonus-Myoclonus Syndrome Associated With Contactin-Associated Protein-Like 2 and Acetylcholine Receptor Autoantibodies in the Setting of Non-Small Cell Lung Carcinoma. Neurohospitalist. 2022 Jan; 12 (1):100-104 Epub 2021 May 07
    View PubMed
  8. Ramos-Fresnedo A, Domingo RA, Sanchez-Garavito JE, Perez-Vega C, Akinduro OO, Jentoft ME, Vora SA, Brown PD, Porter AB, Bendok BR, Link MJ, Middlebrooks EH, Trifiletti DM, Chaichana KL, Quiñones-Hinojosa A, Sherman WJ. The impact of multiple lesions on progression-free survival of meningiomas: a 10-year multicenter experience. J Neurosurg. 2021 Nov 19; 1-9. [Epub ahead of print]
    View PubMed
  9. Chukwueke UN, Vera E, Acquaye A, Hervey-Jumper SL, Odia Y, Klesse LJ, Dunbar E, Sharma A, Fonkem E, Thomas AA, Werbowetski-Ogilvie TE, Camelo-Piragua S, Gatson NTN, de la Fuente MI, Armstrong TS, Porter AB, Jackson S. SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology. Neuro Oncol. 2021 Nov 2; 23 (11):1845-1858
    View PubMed
  10. Tripathi S, Vivas-Buitrago T, Domingo RA, Biase G, Brown D, Akinduro OO, Ramos-Fresnedo A, Sherman W, Gupta V, Middlebrooks EH, Sabsevitz DS, Porter AB, Uhm JH, Bendok BR, Parney I, Meyer FB, Chaichana KL, Swanson KR, Quinones-Hinojosa A. IDH-wild-type glioblastoma cell density and infiltration distribution influence on supramarginal resection and its impact on overall survival: a mathematical model. J Neurosurg. 2021 Oct 29; 1-9 [Epub ahead of print]
    View PubMed
  11. Sharma A, Fruth B, Barrera C, Farfour HN, Mrugala MM, Edwin MK, Sloan JA, Porter AB. How much time do we have? Longitudinal perception of prognosis in newly-diagnosed high grade glioma patients and caregivers compared to clinicians. J Neurooncol. 2021 Apr; 152 (2):313-323 Epub 2021 Jan 23
    View PubMed
  12. Kumthekar P, Dunbar EM, Peters KB, Brastianos PK, Porter AB. A broad perspective on evaluating bias in the neuro-oncology workplace. Neuro Oncol 2021 Mar 25; 23 (3):498-499
    View PubMed
  13. Porter AB, Chukwueke UN, Mammoser AG, Friday B, Hervey-Jumper S. Delivering Equitable Care to Underserved Neuro-oncology Populations. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:1-9
    View PubMed
  14. Hu LS, Wang L, Hawkins-Daarud A, Eschbacher JM, Singleton KW, Jackson PR, Clark-Swanson K, Sereduk CP, Peng S, Wang P, Wang J, Baxter LC, Smith KA, Mazza GL, Stokes AM, Bendok BR, Zimmerman RS, Krishna C, Porter AB, Mrugala MM, Hoxworth JM, Wu T, Tran NL, Swanson KR, Li J. Uncertainty quantification in the radiogenomics modeling of EGFR amplification in glioblastoma. Sci Rep. 2021 Feb 16; 11 (1):3932
    View PubMed
  15. Merrill SA, Sharma A, Carlin RE, McCullough AE, Porter AB, Bendok BR, Kouloumberis PE. A Rare Intracranial Collision Tumor of Meningioma and Metastatic Uterine Adenocarcinoma: Case Report and Literature Review. World Neurosurg. 2021 Jan; 145:340-347 Epub 2020 Sept 25
    View PubMed
  16. Mrugala MM, Ostrom QT, Pressley SM, Taylor JW, Thomas AA, Wefel JS, Coven SL, Acquaye AA, Haynes C, Agnihotri S, Lim M, Peters KB, Sulman EP, Salcido JT, Butowski NA, Hervey-Jumper S, Mansouri A, Oliver KR, Porter AB, Nassiri F, Schiff D, Dunbar EM, Hegi ME, Armstrong TS, van den Bent MJ, Chang SM, Zadeh G, Chheda MG. The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. Neurooncol Adv. 2021 Jan-Dec; 3 (1):vdab035 Epub 2021 Feb 20
    View PubMed
  17. Curtin L, Hawkins-Daarud A, Porter AB, van der Zee KG, Owen MR, Swanson KR. A Mechanistic Investigation into Ischemia-Driven Distal Recurrence of Glioblastoma. Bull Math Biol. 2020 Nov 7; 82 (11):143 Epub 2020 Nov 07
    View PubMed
  18. Singh R, Lehrer EJ, Ko S, Peterson J, Lou Y, Porter AB, Kotecha R, Brown PD, Zaorsky NG, Trifiletti DM. Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches. Radiother Oncol. 2020 Mar; 144:165-179 Epub 2019 Dec 05
    View PubMed
  19. Hoxworth JM, Eschbacher JM, Gonzales AC, Singleton KW, Leon GD, Smith KA, Stokes AM, Zhou Y, Mazza GL, Porter AB, Mrugala MM, Zimmerman RS, Bendok BR, Patra DP, Krishna C, Boxerman JL, Baxter LC, Swanson KR, Quarles CC, Schmainda KM, Hu LS. Performance of Standardized Relative CBV for Quantifying Regional Histologic Tumor Burden in Recurrent High-Grade Glioma: Comparison against Normalized Relative CBV Using Image-Localized Stereotactic Biopsies. AJNR Am J Neuroradiol. 2020 Mar; 41 (3):408-415 Epub 2020 Mar 12
    View PubMed
  20. Sharma A, Mountjoy LJ, Butterfield RJ, Zhang N, Ross HJ, Schild SE, Sio TT, Daniels TB, Paripati HR, Mrugala MM, Vora SA, Patel NP, Zimmerman RS, Ashman JB, Porter AB. Expanding the Spectrum of Radiation Necrosis After Stereotactic Radiosurgery (SRS) for Intracranial Metastases From Lung Cancer: A Retrospective Review. Am J Clin Oncol. 2020 Feb; 43 (2):128-132
    View PubMed
  21. Mackintosh C, Butterfield R, Zhang N, Lorence J, Zlomanczuk P, Bendok BR, Zimmerman RS, Swanson K, Porter A, Mrugala MM. Does location matter? Characterisation of the anatomic locations, molecular profiles, and clinical features of gliomas. Neurol Neurochir Pol. 2020; 54 (5):456-465 Epub 2020 Sept 11
    View PubMed
  22. Singleton KW, Porter AB, Hu LS, Johnston SK, Bond KM, Rickertsen CR, De Leon G, Whitmire SA, Clark-Swanson KR, Mrugala MM, Swanson KR. Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies. Neurooncol Adv. 2020 Jan-Dec; 2 (1):vdaa085 Epub 2020 July 09
    View PubMed
  23. Massey SC, White H, Whitmire P, Doyle T, Johnston SK, Singleton KW, Jackson PR, Hawkins-Daarud A, Bendok BR, Porter AB, Vora S, Sarkaria JN, Hu LS, Mrugala MM, Swanson KR. Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma. PLoS One. 2020; 15 (3):e0230492 Epub 2020 Mar 27
    View PubMed
  24. Valencia-Sanchez C, Gorelkin VC, Mrugala MM, Sharma A, Vora SA, Ashman JB, Daniels TB, Halyard MY, Rule WG, Zhang N, Butterfield RJ, Schild SE, Porter AB. Clinical evaluation of fitness to drive in patients with brain metastases. Neurooncol Pract. 2019 Dec; 6 (6):484-489 Epub 2019 July 03
    View PubMed
  25. Singh R, Lehrer EJ, Ko S, Peterson J, Lou Y, Porter AB, Kotecha R, Brown PD, Zaorsky NG, Trifiletti DM. Brain Metastases from Non-Small Cell Lung Cancer with EGFR or ALK Mutations: A Systematic Review and Meta-Analysis of Multidisciplinary Approaches Radiotherapy and Oncology (accepted). 2019 Nov.
  26. Sharma A, Hu L, Sio T, Ashman J, Vora A, Mrugala M, Porter AB. Radiation necrosis vs tumor progression in patients with brain metastases from treated non small cell lung cancer. AJCO (accepted). 2019 Oct.
  27. Verma A, Sharma A, Porter AP, Robertorye RS, Hilal T. Intravascular Large B-Cell Lymphoma Associated with Systemic and CNS Hemophagocytic Lymphohistiocytosis: A Case Report. Permanente Journal (accepted). 2019 Aug.
  28. Johnston SK, Whitmire P, Massey SC, Kumthekar P, Porter AB, Raghunand N, Gonzalez-Cuyar LF, Mrugala MM, Hawkins-Daarud A, Jackson PR, Hu LS, Sarkaria JN, Wang L, Gatenby RA, Egan KM, Canoll P, Swanson KR, ENDURES consortium. ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma: A Multidisciplinary Team-based, Multifactorial Analytical Approach. Am J Clin Oncol. 2019 Aug; 42 (8):655-661
    View PubMed
  29. Cerhan JH, Anderson SK, Butts AM, Porter AB, Jaeckle K, Galanis E, Brown PD. Examiner accuracy in cognitive testing in multisite brain-tumor clinical trials: an analysis from the Alliance for Clinical Trials in Oncology. Neurooncol Pract. 2019 Jul; 6 (4):283-288 Epub 2018 Nov 24
    View PubMed
  30. Sharma A, Grill MF, Spritzer S, Leis AA, Anderson M, Vig P, Porter AB. Malignant Glial Neuronal Tumors After West Nile Virus Neuroinvasive Disease: A Coincidence or a Clue? Neurohospitalist. 2019 Jul; 9 (3):160-164 Epub 2018 Dec 26
    View PubMed
  31. Dhamija R, Wood CP, Porter AB, Hu LS, Weindling SM, Hoxworth JM. Updated Imaging Features of Dysplastic Cerebellar Gangliocytoma. J Comput Assist Tomogr. 2019 Mar/Apr; 43 (2):277-281
    View PubMed
  32. Ornelas AS, Porter AB, Sharma A, Knox MG, Marks LA, Wingerchuk DM, O'Carroll CB. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma? Neurologist. 2019 Mar; 24 (2):71-73
    View PubMed
  33. Hu LS, Yoon H, Eschbacher JM, Baxter LC, Dueck AC, Nespodzany A, Smith KA, Nakaji P, Xu Y, Wang L, Karis JP, Hawkins-Daarud AJ, Singleton KW, Jackson PR, Anderies BJ, Bendok BR, Zimmerman RS, Quarles C, Porter-Umphrey AB, Mrugala MM, Sharma A, Hoxworth JM, Sattur MG, Sanai N, Koulemberis PE, Krishna C, Mitchell JR, Wu T, Tran NL, Swanson KR, Li J. Accurate Patient-Specific Machine Learning Models of Glioblastoma Invasion Using Transfer Learning. AJNR Am J Neuroradiol. 2019 Mar; 40 (3):418-425 Epub 2019 Feb 28
    View PubMed
  34. Fega KR, Fletcher GP, Waddle MR, Peterson JL, Ashman JB, Barrs DM, Bendok BR, Patel NP, Porter AB, Vora SA. Analysis of MRI Volumetric Changes After Hypofractionated Stereotactic Radiation Therapy for Benign Intracranial Neoplasms. Adv Radiat Oncol. 2019 Jan-Mar; 4 (1):43-49 Epub 2018 Aug 23
    View PubMed
  35. Rayfield CA, Grady F, De Leon G, Rockne R, Carrasco E, Jackson P, Vora M, Johnston SK, Hawkins-Daarud A, Clark-Swanson KR, Whitmire S, Gamez ME, Porter A, Hu L, Gonzalez-Cuyar L, Bendok B, Vora S, Swanson KR. Distinct Phenotypic Clusters of Glioblastoma Growth and Response Kinetics Predict Survival. JCO Clin Cancer Inform. 2018 Dec; 2:1-14.
    View PubMed
  36. Dawit S, Porter AB. Low grade glioma in the setting of Wilson’s Disease. ACR Case in Point (accepted). 2018.
  37. Porter AB, Sio TT, Nelson KD, Raghunathan A, Bendok BR, Mrugala MM. Disseminated High-grade Glioma in a Long-term Survivor of Medulloblastoma: Implications and Management of Radiation-induced Malignancies. Neurologist. 2018 Nov; 23 (6):191-193
    View PubMed
  38. Yang M, Zhou Y, Hoxworth JM, Porter AB, Roarke MC. Hybrid whole body (18)F-FDG PET/MR in evaluation of plexiform neurofibromatosis type 1. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018 Jul - Aug; 37 (4):261-263 Epub 2017 Aug 10
    View PubMed
  39. Dhamija R, Weindling SM, Porter AB, Hu LS, Wood CP, Hoxworth JM. Neuroimaging abnormalities in patients with Cowden syndrome: Retrospective single-center study. Neurol Clin Pract. 2018 Jun; 8 (3):207-213
    View PubMed
  40. Sharma A, De G, Porter A, Grill MF, Rosenthal A, Brown CE, Swanson K, Mrugala MM. CAR-T cell therapy in neuro-oncology: applications and toxicity. Neuroimmunol Neuroinflammation. 2018; 5(43).
  41. Grimsrud KW, Porter AB. Mystery Case: Widespread plexiform neurofibromas in neurofibromatosis type 1: An uncommon cause of back pain. Neurology. 2017 Oct 31; 89 (18):e218-e219
    View PubMed
  42. Uhm JH, Porter AB. Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era. Mayo Clin Proc. 2017 Jun; 92 (6):995-1004
    View PubMed
  43. Porter AB, Lachance DH, Johnson DR. Socioeconomic status and glioblastoma risk: a population-based analysis. Cancer Causes Control. 2015 Feb; 26 (2):179-185 Epub 2014 Nov 25
    View PubMed
  44. Porter A. Brainstem glioma doesn't stop former Marine. Clinical Neurology News. 2012 Aug:7-8.
  45. Flanagan EP, O'Neill BP, Habermann TM, Porter AB, Keegan BM. Secondary intramedullary spinal cord non-Hodgkin's lymphoma. J Neurooncol. 2012 May; 107 (3):575-80 Epub 2011 Dec 22
    View PubMed
  46. Flanagan EP, O'Neill BP, Porter AB, Lanzino G, Haberman TM, Keegan BM. Primary intramedullary spinal cord lymphoma. Neurology. 2011 Aug 23; 77 (8):784-91 Epub 2011 Aug 10
    View PubMed
  47. Porter AB, Bernold DM, Giannini C, Foote RL, Link MJ, Olsen KD, Moynihan TJ, Buckner JC. Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. J Neurooncol. 2008 Nov; 90 (2):201-4 Epub 2008 July 17
    View PubMed
  48. Cady FM, O'Neill BP, Law ME, Decker PA, Kurtz DM, Giannini C, Porter AB, Kurtin PJ, Johnston PB, Dogan A, Remstein ED. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol. 2008 Oct 10; 26 (29):4814-9 Epub 2008 July 21
    View PubMed
  49. Porter AB, Giannini C, Kaufmann T, Lucchinetti CF, Wu W, Decker PA, Atkinson JL, O'Neill BP. Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: a pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma. Ann Neurol. 2008 May; 63 (5):662-7
    View PubMed
  50. Stead LG, Bellolio MF, Gilmore RM, Porter AB, Rabinstein AA. Pharmacologic elevation of blood pressure for acute brain ischemia. Neurocrit Care. 2008; 8 (2):259-61
    View PubMed
  51. Porter A. International Education Issues: a perspective on the practice of neurology in northern Kenya. Neurology. 2007 Oct 23; 69(17):1719-20.
    View PubMed
  52. Porter A, Lyons MK, Wingerchuk DM, Bosch EP. Spinal cord astrocytoma presenting as "idiopathic" intracranial hypertension. Clin Neurol Neurosurg. 2006 Dec; 108(8):787-9. Epub 2005 Nov 18.
    View PubMed
  53. Porter-Umphrey A, Rabinstein AA, Tippmann-Peikert M. Coma, hypertension, and brainstem imaging abnormalities in a paraplegic man with necrotizing fasciitis. Rev Neurol Dis. 2006 Summer; 3(3):129-30; discussion 136-8.
    View PubMed
  54. Porter-Umphrey A, Rabinstein AA, Tippmann-Peikert M. Case discussion: coma, hypertension, and brainstem imaging abnormalities in a paraplegic man with necrotizing fasciitis. Rev Neurol Dis. 2006; 3(3):136-8.
  55. Porter A, Gladstone JP, Dodick DW. Migraine and white matter hyperintensities. Current Pain and Headache Reports. 2005 Aug; 9(4):289-93.
    View PubMed
PST-20225265